Edwards Lifesciences Corporation EW

86.29 0.56 0.65% as of 25 Sep
Market cap
$49.4B
P/E
49.6×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Edwards Lifesciences Corporation (EW) EV/Sales

As of 25 September 2026, Edwards Lifesciences Corporation (EW) trades at a EV/Sales of 7.1×. Over the past ten years it has ranged from 5.3× (May 2015) to 15.8× (December 2021); the current reading is higher than 19% of that period. That is above the Medical Devices industry median of 2.4× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Annual

Period EV/Sales Change
FY2025 7.6× 1.39%
FY2024 7.5× (16.00%)
FY2023 8.9× (11.97%)
FY2022 10.2× (33.43%)
FY2021 15.3× 19.57%
FY2020 12.8× 16.44%
FY2019 11.0× 26.48%
FY2018 8.7× 28.24%
FY2017 6.8× 0.72%
FY2016 6.7× 2.12%

Quarterly

Period EV/Sales Change
Jun 2026 7.4× 8.36%
Mar 2026 6.9× (9.81%)
Dec 2025 7.6× 6.15%
Sep 2025 7.2× (3.87%)
42 more quarters

Against its own ten years

Low 5.3× High 15.8×
Ten-year median 8.6×
Current reading's percentile 19

EV/Sales against peers

Company EV/Sales
PHG Koninklijke Philips N.V. compare 1.4×
GEHC GE HealthCare Technologies Inc. compare 1.9×
ZBH Zimmer Biomet Holdings, Inc. compare 2.9×
MDT Medtronic PLC compare 3.5×
STE STERIS plc compare 3.6×
BSX Boston Scientific Corporation compare 3.7×
SYK Stryker Corporation compare 4.5×
DXCM DexCom, Inc. compare 6.5×
EW Edwards Lifesciences Corporation 7.1×
Medical Devices industry median 2.4×
Healthcare sector median 3.6×
Market median 2.2×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on EW